279 related articles for article (PubMed ID: 35563772)
1. Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma Treatment.
Maresca L; Stecca B; Carrassa L
Cells; 2022 Apr; 11(9):. PubMed ID: 35563772
[TBL] [Abstract][Full Text] [Related]
2. Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences.
Carrassa L; Colombo I; Damia G; Bertoni F
Cancer Treat Rev; 2020 Nov; 90():102090. PubMed ID: 32892059
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach.
Kim KB; Soroceanu L; de Semir D; Millis SZ; Ross J; Vosoughi E; Dar AA; Nosrati M; Desprez PY; Ice R; Chen M; Chetal K; Bhattacharjee A; Moretto J; Leong SP; Singer MI; Parrett BM; Minor DR; McAllister S; Miller JR; Salomonis N; Kashani-Sabet M
J Invest Dermatol; 2021 Aug; 141(8):2028-2036.e2. PubMed ID: 33610559
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.
Cheng B; Pan W; Xing Y; Xiao Y; Chen J; Xu Z
Eur J Med Chem; 2022 Feb; 230():114109. PubMed ID: 35051747
[TBL] [Abstract][Full Text] [Related]
5. Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations.
Ngoi NYL; Westin SN; Yap TA
Curr Opin Oncol; 2022 Sep; 34(5):559-569. PubMed ID: 35787597
[TBL] [Abstract][Full Text] [Related]
6. PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction
Fröhlich LM; Niessner H; Sauer B; Kämereit S; Chatziioannou E; Riel S; Sinnberg T; Schittek B
Cancer Res Commun; 2023 Sep; 3(9):1743-1755. PubMed ID: 37674529
[TBL] [Abstract][Full Text] [Related]
7. DNA damage response as a therapeutic target in gynecological cancers.
Leary A; Auguste A; Mesnage S
Curr Opin Oncol; 2016 Sep; 28(5):404-11. PubMed ID: 27455135
[TBL] [Abstract][Full Text] [Related]
8. Directing the use of DDR kinase inhibitors in cancer treatment.
Brandsma I; Fleuren EDG; Williamson CT; Lord CJ
Expert Opin Investig Drugs; 2017 Dec; 26(12):1341-1355. PubMed ID: 28984489
[TBL] [Abstract][Full Text] [Related]
9. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
[TBL] [Abstract][Full Text] [Related]
10. Homologous Recombination Deficiency (HRD) in Cutaneous Oncology.
Akinjiyan FA; Morecroft R; Phillipps J; Adeyelu T; Elliott A; Park SJ; Butt OH; Zhou AY; Ansstas G
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445949
[TBL] [Abstract][Full Text] [Related]
11. Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy.
Gourley C; Balmaña J; Ledermann JA; Serra V; Dent R; Loibl S; Pujade-Lauraine E; Boulton SJ
J Clin Oncol; 2019 Sep; 37(25):2257-2269. PubMed ID: 31050911
[TBL] [Abstract][Full Text] [Related]
12. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
Padella A; Ghelli Luserna Di Rorà A; Marconi G; Ghetti M; Martinelli G; Simonetti G
J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680
[TBL] [Abstract][Full Text] [Related]
13. New perspective on DNA response pathway (DDR) in glioblastoma, focus on classic biomarkers and emerging roles of ncRNAs.
Pirlog BO; Ilut S; Pirlog R; Chiroi P; Nutu A; Radutiu DI; Cuc GD; Berindan-Neagoe I; Nabavi SF; Filosa R; Nabavi SM
Expert Rev Mol Med; 2023 May; 25():e18. PubMed ID: 37154101
[TBL] [Abstract][Full Text] [Related]
14. The DNA Damaging Revolution: PARP Inhibitors and Beyond.
Yap TA; Plummer R; Azad NS; Helleday T
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():185-195. PubMed ID: 31099635
[TBL] [Abstract][Full Text] [Related]
15. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
Haynes B; Murai J; Lee JM
Cancer Treat Rev; 2018 Dec; 71():1-7. PubMed ID: 30269007
[TBL] [Abstract][Full Text] [Related]
16. ATR/CHK1 inhibitors and cancer therapy.
Qiu Z; Oleinick NL; Zhang J
Radiother Oncol; 2018 Mar; 126(3):450-464. PubMed ID: 29054375
[TBL] [Abstract][Full Text] [Related]
17. The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment.
Li S; Wang L; Wang Y; Zhang C; Hong Z; Han Z
J Hematol Oncol; 2022 Oct; 15(1):147. PubMed ID: 36253861
[TBL] [Abstract][Full Text] [Related]
18. Olaparib-Resistant
Biegała Ł; Gajek A; Marczak A; Rogalska A
Cells; 2023 Mar; 12(7):. PubMed ID: 37048111
[TBL] [Abstract][Full Text] [Related]
19. Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides
Voutsadakis IA; Stravodimou A
Anticancer Res; 2023 Mar; 43(3):967-981. PubMed ID: 36854505
[TBL] [Abstract][Full Text] [Related]
20. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
